Computationally engineered influenza antiviral affords broad prophylactic and therapeutic protection against influenza

• Deborah Heydenburg Fuller,
• Merika Treants Koday,
• Jorgen Nelson,
• Aaron Chevalier,
• Michael Koday,
• Donald F. Smee,
• Amy L. Hartman,
• Douglas S. Reed,
• Kelly Stefano Cole,
• David Baker

Affiliations

Deborah Heydenburg Fuller

University of Washington, Department of Microbiology, Seattle, Washington, USA; University of Washington, Washington National Primate Research Center, Seattle, Washington, USA

Merika Treants Koday

University of Washington, Department of Microbiology, Seattle, Washington, USA

Jorgen Nelson

University of Washington, Department of Biochemistry, Institute for Protein Design, Seattle, Washington, USA

Aaron Chevalier

University of Washington, Department of Biochemistry, Institute for Protein Design, Seattle, Washington, USA

Michael Koday

University of Washington, Washington National Primate Research Center, Seattle, Washington, USA

Donald F. Smee

Utah State University, Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Sciences, Logan, Utah, USA

Amy L. Hartman

University of Pittsburgh, Regional Biocontainment Laboratory, Center for Vaccine Research, Pittsburgh, Pennsylvania, USA

Douglas S. Reed

University of Pittsburgh, Regional Biocontainment Laboratory, Center for Vaccine Research, Pittsburgh, Pennsylvania, USA

Kelly Stefano Cole

University of Pittsburgh, Regional Biocontainment Laboratory, Center for Vaccine Research, Pittsburgh, Pennsylvania, USA

David Baker

University of Washington, Department of Biochemistry, Institute for Protein Design, Seattle, Washington, USA; University of Washington, Howard Hughes Medical Institute, Seattle, Washington, USA